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The airways of persons with cystic fibrosis are prone to infection by a diverse and dynamic polymicrobial
consortium. Currently, no models exist that permit recapitulation of this consortium within the labora-
tory. Such microbial ecosystems likely have a network of interspecies interactions, serving to modulate
metabolic pathways and impact upon disease severity. The contribution of less abundant/fastidious mi-
crobial species on this cross-talk has often been neglected due to lack of experimental tractability. Here,
we critically assess the existing models for studying polymicrobial infections. Particular attention is paid
to 3Rs-compliant in vitro and in silico infection models, offering significant advantages over mammalian
infection models. We outline why these models will likely become the ‘go to’ approaches when recapitu-
lating polymicrobial cystic fibrosis infection.
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Cystic fibrosis (CF) is the most common life-limiting genetic disease within the Caucasian population and is
estimated to affect 70,000 people worldwide [1]. It results from an autosomal recessive defect within the cystic
fibrosis transmembrane conductance regulator (CFTR) gene [2] and a myriad of different mutations have been
described that bring about the onset of CF [3]. Dysfunctional CFTR activity leads to complications in multiple
organs, but perhaps the most striking presentation of CF is the overproduction of a nutrient rich, viscous mucus
in the CF-airways [4]. Defective mucociliary clearance mechanisms further contribute toward airway obstruction
which results in the CF airways being a highly heterogenous environment, typically characterized by steep oxygen
gradients, lowered pH and an abundance of mucin, amino acids, nitrate and iron [5–10]. This unique environmental
niche is prone to chronic microbial colonization, and such infections contribute toward the death of 80–95% of CF
patients [11–15] through triggering bouts of excessive inflammation, termed acute pulmonary exacerbations (APEs).
Cumulatively, these lead to tissue destruction and a steady decline in lung function [14,15].
Traditionally, culture-based microbiological investigation of sputum samples expectorated from CF-patients
have been used to establish which microbial species are associated with chronic infection of the CF airways. It
was suggested, in line with Koch’s postulates, that single-microbial species were the primary cause of infection [16],
with Staphylococcus aureus being prevalent in the early stages of life, before being outcompeted as Pseudomonas
aeruginosa (PA) becomes the dominant pathogen alongside occasional co-infections from other ‘keystone’ respiratory
pathogens [17–19]. More recently, culture-independent molecular profiling techniques, for example, sequencing of
the hypervariable bacterial 16S rDNA and fungal ITS regions, suggest that a previously unanticipated diverse
polymicrobial population of both bacteria and fungi are associated with CF-airway infections [14,15,18–22]. However,
this notion has been strongly contended by the recent work of Jorth et al., who sampled lavage fluid directly from the
lungs of CF-children displaying stable lung function. These authors suggest that the previously reported diversity
of the CF-associated microbiome may arise from the sampling of oral contaminants. This notwithstanding, Jorth
et al. did suggest that a core population of ‘nonconventional’ bacterial species are found alongside the traditional
CF-pathogens [23].
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With the CF airways containing a polymicrobial ecosystem, it could be hypothesised that members of this
community interact with one another either through quorum sensing, the recognition of cell surface proteins
and the secretion of other small metabolites. Indeed, it has been demonstrated that the co-culture of different
bacterial species leads to large alterations in their gene expression profile, both in vivo and in vitro [24]. Such
changes can be synergistic or antagonistic in nature [25,26] and may cause members of the community to adopt
different lifestyles and activate distinct metabolic pathways. These changes could alter the expression of virulence
factors and influence the chemical environment, causing deviations from behaviors observed when studying single
species in isolation [21,25,27–30]. For example PA is able to sense the presence of peptidoglycan shed from Gram-
positive bacteria. This stimulates the production of extracellular factors that are lytic against both prokaryotic and
eukaryotic cells [31]. Ultimately, polymicrobial infections display altered responses to therapeutic interventions.
Such interventions are often aimed at decreasing the microbial load of a principal pathogen, and differentially
impact disease severity between patients [32].
The microbial consortium present within the CF airway is thought to consist of both stable and disturbed
states [25], yet little is known about what triggers the switch between the two. A better understanding of the extent
of interactions occurring within the CF airway, and of how the architecture of polymicrobial communities adapts
over time and responds to clinical intervention, may lead to the identification of novel therapeutic targets. It is
possible that less abundant and poorly characterized species, typically viewed as avirulent when studied in isolation,
could trigger the adoption of a more pathogenic lifestyle by known pathogens or in species classically thought to be
nonpathogenic or nonconventional. Through targeting the pathways involved, and the chemical changes inducing
the onset of a decline in lung function, it may be possible to delay or prevent key CF pathogens from dominating
the patient’s airways.
Despite the likely role played by interspecies interactions on the severity of disease within CF and other
polymicrobial infections, relatively little is understood about this, or about how interspecies interactions impinge
upon adaptation in the airways. This lack of understanding is, at least partially, attributable to the complexity
of mixed-species interactions, and the paucity of polymicrobial models available for studying such interactions.
Although research focus is now gradually moving away from studying single species in isolation, and moving
more toward cocultivating the major members of mixed populations, these studies often ignore the presence of
less abundant and hard-to-cultivate members of the community, thereby neglecting their impact as drivers of
population change.
It would be of enormous benefit for models to be developed within the laboratory that enable the stable
recapitulation of the whole polymicrobial community derived from the airways of CF-patients, in other words, those
associated with sputum or bronchoalveolar lavage fluid (BALF) samples. These models would better represent the
nature of the CF airway community and shed light on how both key pathogens and less represented species
might be influenced by external perturbations. Such a model system would allow for a multitude of biological
questions to be addressed relating to interspecies interactions and evolution within mixed microbial populations.
The community-wide impact of external perturbations, either through antimicrobial treatment or through the
introduction of new species/strain variants, could all be studied in a robust and reproducible manner.
This commentary aims to provide a critical overview of the existing models used to study microbial infection in
relation to CF, and we hope to clarify how such approaches might be utilized to develop true polymicrobial infection
models utilizing the microbial communities derived from CF sputum. Close attention is paid to the development
of in vitro and in silico infection models that comply with the 3Rs guidelines for the reduction, replacement and
refinement for the more humane use of animal models within research. Additionally, we highlight the need to
consider CF as a mixed-species infection scenario, in order to identify novel targets for therapeutic intervention
and understand the progression of disease within a more physiologically relevant context.
Mammalian CF infection models
Animals have long served in the field of comparative biology as a proxy for studying human genetic disease, and CF
is no exception to this trend. In 1992, just 3 years after the identification and initial characterization of the CFTR
gene, the first CF-mouse model was generated through gene targeting of embryonic stem cells to abolish CFTR
activity [33]. In recent years, countless advances in gene editing techniques have led to the generation of a wealth of
CF-animal models aimed at mimicking the mutations associated with the disease in humans, with varying success.
However, some of these CF-animal models have been pivotal in furthering our understanding of the underlying
mechanisms of CF pathology and the development of therapeutics now approved for the treatment of patients
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carrying a distinct subset of CFTR mutations. This notwithstanding, our aim here is to provide an overview into
how models can be used to study CF-associated infections, and as such we will not review further the utility of
animal models for developing gene therapy treatments [34–36].
The comparatively low cost, rapid reproduction rate and ease of genetic manipulation ensure that mice are usually
the first point of call when developing transgenic mammalian models. To date at least 14 different CF-mouse models
have been reported, with differing CFTR mutations and genetic backgrounds available [37]. Despite this impressive
selection of models at hand, numerous issues have plagued the use of mice for studying CF-associated microbial
infections. The biggest issue seems to arise from differences in the spatial structure of murine airways and an
inability to spontaneously develop airway infection [33], even with CF-mice demonstrating impaired mucociliary
clearance. The CFTR protein is known to play a key role in innate lung immunity and several studies have since
been undertaken to determine why even the ‘β-NaEC’ mouse [38] and other backgrounds lacking residual CFTR
expression fail to develop infection [39,40].
Lack of an existing microbial community could be considered a ‘clean-slate’ for inoculating CF-mice with
polymicrobial communities derived from patients. However, the introduction of pathogens into these mice leads
to rapid microbial clearance [41], and repeat infections cause death [42]. Infection timescales using murine hosts can
be considered semi-chronic at best, with successful infection (when achieved) typically lasting no more than a few
days and reliant upon immobilizing the bacteria (PA) within agarose/alginate/agar beads that are directly instilled
into the lung [41–50]. Using specific hypermucoid strains (e.g., NH57388A) it has been possible to maintain strain
specific PA infections of up to 3 months within a host that bears the hallmarks of chronic CF infection [44,50]. An
alternative inoculation approach that avoids the mechanical immobilization of microbial species and attempts to
better represent a natural route of infection is the intranasal inoculation of mouse models. A persistent infection
lasting 28 days could be established in non-CF mice following the respiratory inhalation of the transmissible
Liverpool epidemic strain (LES) of PA [51]. Bacteria were found to be harbored in the nasopharynx throughout
the experiment, and no PA could be detected in the lungs even by day 14. However, on day 28, PA could once
again be isolated at low levels from the lung (26 CF per lung). These findings demonstrate that persistence in
the nasopharynx allows reseeding of the lower airways and support the hypothesis that the upper respiratory tract
provides a ‘silent reservoir’ able to harbor CF-associated species that can then be aspirated in to the lungs of CF
patients. It would certainly be interesting to compare how a CF-mouse model responds to the respiratory inhalation
route of infection and if multiple microbial species could be maintained within the nasopharynx. The intranasal
inoculation of PA isolates recovered longitudinally over the course of a patient’s life into CF-mice revealed that
only late-stage ‘CF-adapted’ isolates could establish persistent infection [45,49]. It has also been suggested that older
CF-mice may be more predisposed to microbial infection, but little work has been carried out to determine if such
mice have an expanded range of infective capabilities [47,52].
Co-infection studies have been trialed in recent years, but again these have been limited to an acute infection
timescale (often just 18 h) until the clearance of non-PA species occurs. Importantly, these studies have revealed
that co-infection of PA with S. aureus or Burkholderia cenocepacia enhances the murine immune response and
upregulates virulence factor production in the lungs [43,48,53]. Furthermore, in vivo coinfection studies of PA and S.
aureus found that ‘late-stage’ PA isolates had undergone phenotypic adaptation associated with enhanced persistence
in the CF lung, and demonstrated a reduced capacity to outcompete S. aureus during co-culture [48]. Interestingly,
immobilizing B. cenocepacia in PA-derived alginate caused increased microbial persistence, inflammation and
mortality rates [46]. Such studies provide clear evidence that interspecies interactions drive modulations in microbial
lifestyles, and that these changes have a major impact upon disease severity.
Mouse infection models aim to provide an insight into the mechanisms underlying host-responses to infection
but are severely limited by the small subset of PA isolates proven to be able to establish an infection once physically
immobilized. Further research is required into how CF mice rapidly clear airway infections; this may lead to the
generation of novel transgenic models with an improved propensity for sustaining mixed species infections. Until
this is achieved, CF mice need to be considered with caution as models for polymicrobial CF infection. The impact
of this is that researchers need to consider critically the impact that other members within a mixed community have
on driving PA adaptation and host-immune responses in these systems, due to concerns regarding the physiological
relevance of the model.
The inability of CF mice to spontaneously develop lung disease comparable to that observed in human patients
led researchers to develop CF models within larger mammals that share a higher degree of airway similarity with
humans. CF models have now been reported in ferrets [54–56], pigs [57–60] and more recently sheep [61], all with
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higher levels of CFTR homology with the human gene (92, 91 and 91% respectively, and in contrast to just 78%
in mice). Crucially, these larger mammals do develop spontaneous airway infections, demonstrating a reliance
on functioning CFTR protein for effective airway clearance. Despite their apparent predisposition for microbial
infection, these models are not without limitations and multiple issues hamper their use in studying polymicrobial
CF-associated infections.
Soon after birth, CF ferrets develop spontaneous bacterial infection and severe lung pathologies mirroring
those observed in humans. Examination of BALF established that members of the Streptococcus, Staphylococcus,
Enterococcus and Pseudomonas genera were present at low levels and could not be eradicated from the airways [53–55].
This presence of a diverse airway microbiota suggests CF ferrets are permissive for microbial colonization, yet
they are limited in their suitability for the inoculation of human-derived polymicrobial communities. Abnormal
inflammation is believed to begin in utero, before being excessively amplified upon bacterial exposure at birth [55].
Single-species intratracheal microbial challenges with PA and B. cenocepacia in CF ferrets led to a hyperinflammatory
response from the host macrophages and increased mortality rates [40], supporting the notion of bacterially driven
immune modulation. The extreme severity of bacteria-associated lung pathologies result in neonatal CF ferrets
relying on antimicrobial therapy to survive weaning [62], limiting their use in studying chronic infection. No studies
have challenged a ferret model with a microbial co-culture, although given the spontaneous development of neonatal
infection, it may be possible to develop acute infection models with polymicrobial communities derived from CF
patients. It would be interesting to compare whether there are any similarities between the hyperinflammatory
response(s) observed in CF ferrets with those observed during APEs in CF patients. In this regard, the acute
ferret infection model could potentially provide a physiologically relevant framework for understanding better the
mechanisms of host-microbe responses leading up to APEs.
Gut-corrected, humanized CF pig models provide an in vivo system that parallels human CF lung pathophysiology
remarkably well. CF pigs develop spontaneous airway infections with diverse and varied microbial populations a
few months after birth, and fail to eradicate bacteria as effectively as wild-type pigs [57–60]. The microbiota of older
CF pigs mostly resembles that of adolescent human patients, with S. aureus being the most commonly isolated
pathogen [20,57,59]. Infection studies have not yet been carried out on CF pigs, although introducing PA isolates
into the established microbial population in vivo would provide unique insight into how this key CF pathogen
initially adapts within the CF airways. Alternatively, a polymicrobial community derived from CF patients could
be introduced into CF pigs to examine the host-microbe response and interspecies interactions that occur within
an environment that is close to being physiologically representative of the human CF lung. However, the high costs
and requirement for specialized expertise and dedicated lab space for conducting research using porcine models
has restricted experimental sample size, widespread uptake, and length of studies; more so than many other in vivo
models.
Plant & invertebrate infection models
With key differences in physiology being apparent between plants/invertebrates and the human airways, the use of
such hosts cannot (strictly speaking) be considered CF-infection models. However, their low cost, basic equipment
requirements and minimal technical skill requirements, as well as a lack of ethical concerns, means such models
provide a highly attractive, high-throughput approach to screen mutant libraries for genes essential for virulence
and growth in vivo.
Limited similarities exist between the immune response of mammals and such simple host systems, yet they
do enable some insights into the host-response to infection. How closely invertebrates approximate mammalian
models is still cause for debate. These models are primarily limited by which microbial species have the capability
to establish an infection, and there is little chemical or spatial similarity in the infection environment compared
with human hosts. The small size of invertebrate models means very low microbial inoculums are rapidly fatal [63]
and ensures that in general only acute, single-species infection studies can be readily undertaken. Mutant knockout
libraries of ‘rare’ or less abundant CF-associated microbial species simply do not currently exist, and cannot be
subject to systematic screens or included within co-infection studies, in spite of the likely role(s) played by these
species in modulating pathogenesis during CF infection. The result of library screens using plant and insect hosts
must be viewed with caution as essential genes for infection within mammalian models may have been missed,
yet such high-throughput screens are certainly useful in the identification of potential virulence genes that can be
further characterized in vitro or in larger in vivo model systems.
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Multiple plant-based infection assays have been reported, including: Arabidopsis thaliana [63], lettuce stems [64]
and mung bean seedlings [65]. With a limited range of human pathogens able to establish infections within these
models, the majority of studies simply focus on PA isolates and mutants. Infection assays often compare the extent
of destruction within stem or leaf infiltration assays or compare the growth of seedlings infected with wild-type or
mutant strains, enabling a rough quantitative measure of the contribution that specific genes have toward causing
virulence in vivo. However, as several mutants can be introduced into the same model, for example, multiple mutant
strains inoculated within a single lettuce stem [64], plants provide an extremely rapid fitness screening system for a
limited number of microbial species.
Caenorhabditis elegans is a very well-characterized, well-established laboratory model organism and is susceptible
to infection by a range of both bacterial and fungal species [66,67], including some that have been isolated from
the CF-lung and are associated with worsened patient prognosis. Microbial species are introduced as a top lawn
or bacterial suspension containing the nematodes during feeding, limiting infection studies to species that can
be successfully cultivated in vitro. In order to establish a co-culture within C. elegans both species must first be
successfully grown together without one outcompeting the other and is something which may not be possible
for the polymicrobial communities associated with CF. Vega and Gore describe the successful co-culture of two
members of the Enterobacteriaceae in C. elegans [68]. However, they also report the dominance of one species over
the other within the intestine during ‘slow colonization’ further demonstrating the limitation of nematodes as a
vehicle for maintaining both the rare and the dominant microbial species associated with CF. When grown on
nutrient-rich media, PA isolates cause ‘fast-killing’ of nematodes due to the production of hydrogen cyanide and
phenazine compounds [69], yet when grown on minimal media PA replicated within the digestive tract to cause
‘slow-killing’ [70]. Such results demonstrate that nematodes are susceptible to death from secreted metabolites and
that the growth media used in the screening of mutant libraries must be carefully considered.
Galleria mellonella (waxmoth larvae) are an alternative invertebrate model used for studying key CF-pathogens.
Although waxmoths are infected by a limited range of pathogens, they are susceptible to infection from PA and some
fungal species associated with the CF-airway [71]. Comparative studies have established that the waxmoth infection
model shows good correlation of antimicrobial efficacy, pharmacokinetics [72] and essential virulence requirements
with mouse models [70], suggesting this system is more representative of mammalian infection than the plant or
nematode models. However, waxmoths are extremely susceptible to infection, with as little as ten bacterial cells
being fatal, thus limiting use of this model to acute single-species infection only. This notwithstanding, serial
passage of microbial populations through waxmoths could be used to represent a more chronic infection, and
reports suggest the phenotypic adaptation of PA isolates does reflect limited elements of evolution within the CF
airways [73].
Drosophila melanogaster presents the most plausible invertebrate model for studying polymicrobial infections.
Not only are there a large number of genetic tools available for the generation of mutant flies (enabling detailed
genetic dissection of host-microbe interactions occurring during infection), but successful S. aureus-PA coinfection
models have been reported [31,74]. These studies build upon previously described single-species feeding models
which demonstrate that bacteria replicate within the fly-crop and cause host mortality. Using this invertebrate
co-infection model it was found that PA can sense peptidoglycan shed from the walls of Gram-positive species,
triggering an enhancement in toxin and antimicrobial production [31]. This not only causes a 1000-fold decrease in
the Gram-positive flora, it also enhanced host mortality. A mutant PA strain, PA601, which lacks the peptidoglycan
receptor, did not increase mortality rates upon co-infection with S. aureus, and these results were verified using a
murine infection model [75]. Such co-infection studies not only provide strong evidence for the need to understand
interspecies interactions in a suitable host model, but also provide clear insights into the mechanisms underpinning
these. The Drosophila model also relies on feeding bacteria to the host, again severely limiting which species can be
studied and preventing this model from being utilized for inoculation with patient-derived polymicrobial samples.
As with all infection studies, it can be difficult to pinpoint which of the multifarious biological interactions that
occur within a host model are crucial for driving changes in human disease severity. A reductionist approach could
be taken to systematically screen mutant libraries within an invertebrate co-infection model to identify key genes
for subsequent study in more advanced model systems. In vivo models provide a system for studying host-microbe
interactions, but they are ill-suited to analyse interspecies microbe–microbe interactions. This is because the added
complexity of an immune response strongly limits the likelihood of sustaining a polymicrobial model mimicking
the chronic infections often associated with CF patients. With emerging evidence suggesting that co-infection
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drives changes in microbial lifestyles, that in turn impact upon disease severity, models that enable the real-time
tracking of microbial populations are urgently required.
In vitro & ex vivo models of CF-infection
Emerging evidence suggests that chemical, not spatio-temporal, challenges have the greatest impact on driving
changes in microbial lifestyles [76,77]. Inherent natural variation between in vivo models leads to local variations in
the chemical environment and immune responses, adding an additional layer of variability. There is clear need for a
robust and reproducible model recapitulating a physiologically relevant environment that allows the chemical and
genetic changes within a mixed population to be dissected. In vitro models present a defined and easily perturbable
environment, that can potentially provide simple, tractable and high-throughput systems for studying mixed species
populations derived from CF patient sputa. The real-time tracking of a model microbial population would allow
a number of fundamental biological questions to be addressed, making it possible to identify novel therapeutic
avenues that might be missed in in vivo infection models.
A number of microbial species associated with CF-airway infections are known to have a narrow host-range of
infection, for example, Haemophilus influenza does not infect nonhuman hosts. Therefore, it may be impossible to
develop certain in vivo polymicrobial infection models. Conversely, several species have been identified in in vivo
CF-models that are not known to infect humans, adding an extra layer of complexity when trying to recapitulate
human infection-associated microbial consortia in vivo. Rearing animal models under gnotobiotic conditions
can potentially reduce the presence of animal-specific species, although this does add significantly to the cost of
maintaining the model.
A combination of targeted and untargeted culture-independent molecular approaches can be used to follow
the composition of a polymicrobial community over time in an in vitro infection model. Culture-independent
molecular analyses allow the influence of less abundant and hard-to-isolate species to be tracked effectively within
models representative of chronic infections. The utility of untargeted molecular approaches, such as sequencing
the hypervariable 16S rDNA and ITS regions of bacteria and fungi (respectively), has been reviewed by Rogers et
al. [21]. Moreover, the development of revolutionary, high-throughput and sensitive targeted gene assays such as the
NanoString nCounter system allows the expression of up to 800 different genes to be studied in a single reaction [78].
Utilizing probes designed against known 16S rDNA and ITS regions alongside key virulence genes has allowed
accurate determination of the microbial consortium associated with CF-sputum samples [79], alongside tracking
the composition and transcriptome profiles of complex, mock microbial communities [80]. Probes targeting mRNA
molecules provide a more sensitive indication of the metabolically active members of a community, identifying the
key drivers that potentially influence community adaptation and responses to environmental challenges.
Artificial sputum medium (ASM) or synthetic cystic fibrosis sputum (SCFM), is a highly defined synthetic
growth medium that closely mimics the nutritional composition of sputum found in the CF-airway [76,81–85].
Comparison of the essential genome of PA isolates following growth in patient-derived sputum or ASM found
virtually no difference between the two [83], providing compelling evidence that ASM is a physiologically relevant in
vitro culture medium to support the growth of CF isolates. This notwithstanding, Cornforth et al. recently showed
that machine learning approaches can discriminate PA grown in vivo from PA grown in vitro in ASM based on
transcriptional profiling. However, little account was taken in that study of possible differences in the in vivo/in
vitro transcriptome data arising from the presence of less abundant non-PA species in the human samples [86].
ASM induces PA to grow as microcolonies closely associated with the mucin, strongly resembling the growth
observed in CF-sputum [81]. However, numerous modified recipes for ASM have been proposed, each of which is
associated with distinct changes in microbial growth phenotype [82,87], thus demonstrating the need to standardise
this complex media to ensure reliability and reproducibility between in vitro experiments. In vitro models allow
facile experimental tuning of growth conditions to mimic different disease states; something that is simply not
possible using in vivo models. Using ASM, the long-term maintenance of both PA and S. aureus in mixed species
biofilms has been made possible [84], something previously not attainable using conventional laboratory media [88]
despite the co-isolation of both species from the airways of ∼31% of CF-patients [89]. Although no published
studies have yet attempted the cultivation of a CF-associated polymicrobial community within ASM, similarities
in nutrient availability allow us to postulate that in these conditions, the microbiota might be experimentally
maintained in vitro. Direct inoculation of the ‘complete’ microbial community contained within sputum samples
would permit inter-species cross-feeding to occur between cohabiting organisms. This may permit the growth of
fastidious and auxotrophic strains known to be associated with the CF-airways [90].
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In addition to the ease with which in vitro models can be experimentally perturbed, such systems are free
from the temporal limitations imposed by animal infection studies. Longitudinal sampling of an in vitro model
inoculated with a diverse polymicrobial community would reveal the chain of evolutionary events preceding the
latest sampling point, essentially allowing a direct experimental analysis of Gould’s speculations about ‘rewinding
the tape of evolution’. Whether parallel, identically inoculated multi-species populations that are subject to the same
(intensely competitive) selection pressures can demonstrably follow the same independent evolutionary trajectory
becomes an experimentally tractable problem. Such studies that examine compositional and genetic changes within
communities can also be supported with chemical analyses to link how these changes affect the chemical environment
of the airways. A novel Winogradsky-based culture model (WinCF) using a number of different chemical indicators
has been used to monitor the growth of sputum samples in ASM. The study revealed a 2 unit reduction in the
pH and 30% increase in gas production due to the increased abundance of fermentative anaerobes present in the
sputum prior to the onset of APEs [76]. We also note that sequential sampling the secretome of a polymicrobial
community is possible within an in vitro model, allowing a direct analysis of the impact of inter-species interactions
on virulence factor secretion.
Introducing sputum samples taken from disease states within the same CF patient, in other words, before,
during and after APEs, into an in vitro system would allow differences in the polymicrobial composition to be
studied and could shed light into how subtle differences within these complex communities contribute to a decline
in lung function. Sousa et al. utilized ASM to develop a long-term (10 days) in vitro culture system mimicking
the physiological conditions of the airways to determine how clinically used antibiotics affected the phenotypic
diversification of PA isolates [85]. That study found that sub-inhibitory concentrations of ciprofloxacin drove
diversification in CF isolates but not in laboratory reference strains. Similar studies using polymicrobial cocultures
could be undertaken to examine how therapeutic intervention drives phenotypic changes within the total microbial
consortium associated with CF airways.
New species or strain variants, including ‘keystone’ CF pathogens such as PA, could be introduced into an
established steady-state in vitro polymicrobial community to simulate the events following initial introduction of
such variants in the patient airways. Such events are very difficult indeed to capture through direct analysis of
patient sputa. Furthermore, such an in vitro model provides the unparalleled opportunity to study the genetic and
phenotypic changes that occur in both the ‘invading’ species and in the endogenous polymicrobial population.
Similarly, hypermutator strains, for example, mutS mutants [91], could be introduced into CF derived polymicrobial
populations to examine the impact of what happens to all the species present when one of them is allowed to ‘step
on the evolutionary gas pedal’. A knowledge of the order of succession of major CF pathogens in a polymicrobial
community may reveal clinically relevant insights into the types of interspecies signaling pathways involved in
maintaining stable community architectures [92].
Biofilm formation may be the biggest contributor toward enhancing infection persistence, decreasing antimicro-
bial susceptibility, and elevating mutation rates within the CF airways [26,29,84,93–96]. Unsurprisingly the formation
of biofilms has been extensively studied in vitro, with a focus in recent years on moving away from mono-species
biofilms in favor of co-cultures more representative of real infection scenarios [53,77,84,94–98]. Using mixed-species
biofilm models it has been found that species co-isolated from the CF lung can either increase or decrease the antimi-
crobial susceptibility [77,95] and the production of biomass [52,84,95] by other species present, and that strain variants
provide cross-protection against different host-generated antimicrobials [98]. Furthermore, in vitro co-cultures of
PA–S. aureus biofilms show that the mutation rates within these species can be increased up to 500-fold, and that S.
aureus adopts a drastically different growth phenotype reminiscent of isolates recovered directly from the CF lung.
To date, there is only one report in which a polymicrobial biofilm derived from CF sputum has been reconstituted
in vitro [99]. That study focused on how antimicrobials affect the population, and growth conditions were not
optimized to represent the physiology in the CF airway. By more closely recapitulating the CF-associated chemical
environment, it may be possible to maintain polymicrobial biofilms more representative of those residing in the
airways of CF patients.
One major limitation of in vitro models is the lack of spatial organization closely resembling that of a host, and
which is provided to some degree in in vivo infection models. To overcome this deficiency of in vitro model systems,
an ex vivo infection model has recently been developed [100] to provide a tractable and high-throughput system
that can be easily used to mimic the airway architecture within a laboratory environment. Using porcine lungs, a
waste by-product of the food industry, and ASM, this ex vivo model provides an effective and ethical solution to
introducing spatial organization into longitudinal culture studies. Furthermore, different sections of lung tissue can
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be used to mimic either upper or lower respiratory tract infections [101]. So far only PA isolates have been cultured
within this model and these results demonstrate that ex vivo models are an effective experimental approach to study
CF infection. It would be fascinating to introduce the polymicrobial community derived from CF sputum into an
ex vivo model and assess how this shapes the trajectory of, for example, PA evolution.
Perhaps the largest barrier to the use of in vitro polymicrobial infection models is a lack of host cells that likely
play a role in influencing the composition and behavior of the microbial consortium. In vitro models will prove
crucial for the study of microbe-microbe interactions and will effectively reveal information about how species are
able to interact with one another. In vivo models on the other hand are not as well suited to study interspecies
interactions, nor are they as experimentally reproducible or tractable. They do (however) allow a more direct insight
into how hosts respond to infection. A combination of both in vitro and in vivo polymicrobial models would allow
for changes in microbial populations and in the chemical environment to be correlated with host responses.
Human cell–culture infection models provide an alternative approach to introduce elements of the host response
into in vitro studies, and in the future, may allow more direct investigation of human–microbe interactions. Such
in vitro cell culture infection models have already been successfully used to study a monolayer of human bronchiole
epithelial cells homozygous for the F508 CFTR mutation infected with a co-culture of S. aureus and PA [102]. It was
found that PA decreases the viability of S. aureus and causes the species to adopt fermentative metabolic pathways.
These results strongly correlate with changes reported to occur prior to the onset of APEs, and provide clear
evidence that this type of in vitro infection model may effectively represent the CF airway environment. Advances
in cell culture procedures and gene editing tools mean that it may soon be feasible to routinely culture cell lines
derived directly from individual CF patients [103], which could, in turn, be infected with polymicrobial populations
gathered from the sputum of the same patient. The generation of such ‘personalized infection models’ would allow
an unparalleled advantage over the use of ‘generic’ cell-lines and in vitro models to study microbial populations,
allowing a more efficacious testing of antimicrobial action prior to treatment, bridging the ‘bench-to-bedside’ gap.
In silico polymicrobial models
The study of polymicrobial communities is not simply confined to ‘the wet lab’. With our understanding of
microbial metabolic pathways being continually refined, new, more accurate in silico modeling of polymicrobial
communities is becoming readily available. Advancements in the semi-curation of complex microbial communities,
using software such as ModelSeed and AGORA, have led to the metabolic modeling of CF-associated bacterial
communities from published 16S rDNA data [104]. With better formulation for ensuring host-derived metabolite
balance across the community (through use of SteadyCom software), sample-specific heterogenous communities
can be generated that accurately predict which CF-pathogens come to dominate a polymicrobial community. In
silico models are becoming a highly valued tool to derive metabolic inferences that may be difficult to obtain or
observe experimentally and provide a theoretical framework for interpreting in vitro studies.
Computational predictive models are limited by the type and quality of data gathered from experimental studies.
This means that they poorly predict the rare and hard to cultivate microbial species present within CF-associated
microbial communities. Additionally, strain variants and evolutionary ‘cheats’ cannot yet be accounted for within
in silico models, meaning that these models do not predict or incorporate phenotypic adaptation among the
species present. Similarly, the striking spatial heterogeneity reported within the airways of CF patients is not easily
captured in in silico models. Despite these limitations, in silico models do provide a useful a framework for further
experimental analyses, informing on experimental design and interpretation.
Conclusion & future perspective
Culture-independent examination of sputum samples expectorated from CF patients have revealed that a diverse
and varied microbial population (including bacteria and fungi) is associated with the airways of CF patients [14,15,18–
22]. Increasing evidence suggests that interspecies interactions between members of this microbial consortium elicit
mutual influence on the gene expression profile and metabolic pathways adopted by both pathogenic and typically
nonpathogenic species. It is now clear that CF-associated infections must be considered as polymicrobial in nature,
and that a better understanding of how microbial cross talk impacts upon the expression of virulence factors will
be essential if we are to develop improved therapeutic interventions.
A lack of models enabling the stable, long-term cultivation of polymicrobial communities derived from CF
patients, as well as some historical bias, has meant that until recently, most researchers focused their studies on the
primary CF-associated pathogens, for example, PA and S. aureus, neglecting the impact of less abundant or more
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fastidious species. The generation of such polymicrobial-infection models would be of enormous benefit to the
research community, allowing the physiologically representative response(s) of the whole microbial community to
common therapeutic interventions to be more effectively monitored. Furthermore, the phenotypic adaptation and
evolutionary events leading to dominance of key pathogens, or the onset of a decline in lung function could be
picked apart and better understood. Through understanding how interspecies interactions and changes within a
microbial population lead to a worsened disease status, it may be possible to identify novel or improved therapeutic
interventions to help alleviate disease symptoms and improve the quality of life for CF patients.
Animal models of CF are paramount for studying the pathophysiological progression of the disease within
mammalian systems. However, as discussed earlier, the closer these models come to mimicking the human disease,
the more complex and experimentally costly they become. Improvements in CF pigs and the development of CF
sheep likely present the best chance for the development of an effective animal-based infection model, yet a lack
of experimental evidence within the literature makes it difficult to conclude whether this will ever be realized. The
introduction of PA to the existing microbiota of CF pigs would certainly help to reveal if an in vivo polymicrobial
infection model could be attained in principle.
In vitro models provide a feasible approach for the recapitulation of sputum-derived polymicrobial communities
within the laboratory, especially given the development of ASM and ex vivo porcine lung models. In vitro models are
cost-effective, lack ethical concerns (i.e., are 3Rs-compliant) and hopefully will allow for high-throughput, chronic
models of infection to be easily set up without the need for specialized animal handling facilities. A highly defined,
experimentally tuneable chemical environment and lack of host-to-host variability means in vitro models would
provide the perfect system to identify subtle, but key, changes occurring in the community.
Over the course of the next decade we predict that a viable and physiologically representative in vitro polymicrobial
models will be developed and see widespread uptake. Such models will hopefully allow the economical recapitulation
of an entire CF-associated polymicrobial community in the laboratory environment. Key areas to be examined
using such an experimental model would include: understanding how the introduction of PA to an established
polymicrobial population influences changes in community architecture and the chemical environment (secretome,
nutrient availability etc), how the microbial population responds to external stressors such as antimicrobial agents,
identification of the signaling pathways driving key phenotypic adaptations, and so on. Following their successful
development and implementation, such in vitro models may allow novel therapeutic avenues to be explored,
potentially leading to an improvement in quality of life for CF patients and possibly other chronic respiratory
diseases involving polymicrobial infection.
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Executive summary
Cystic fibrosis is a polymicrobial disease
• Culture-independent profiling has revealed a diverse and varied polymicrobial community is associated with the
cystic fibrosis (CF) airways.
• Members of this community interact with one another, causing modulations in gene expression that potentially
impact upon disease severity.
• No models currently exist that permit the recapitulation of a true CF-associated polymicrobial community in the
laboratory.
Murine models of CF
• CF mice are incapable of developing spontaneous airway infections and microbial challenges are rapidly cleared.
• Only Pseudomonas aeruginosa isolates immobilized within beads that are instilled into the lung allow a
semi-chronic infection scenario to be established.
• Although mice provide limited insights into the host-response to infection, murine models are not suited for the
development of polymicrobial infection models.
Ferret & pig models of CF
• Both CF ferrets and CF pigs develop spontaneous airway infection with a range of microbial species soon after
birth.
• Infections in CF ferrets induce fatal, hyperinflammatory immune responses that severely limit their use for
development as polymicrobial models.
• The airway microbiota of CF pigs most closely resembles that of adolescent human patients, although infection
with P. aeruginosa has not been examined.
• Costs and complexity hinder the uptake of CF pig models, and as a result, little research has been undertaken into
airway infections using this model.
Plant & invertebrate models of CF
• Plant and invertebrate models provide high-throughput platforms to screen mutant libraries for a limited range
of genes required for in vivo growth and virulence.
• Plant and invertebrate models support the growth of only a limited spectrum of CF-associated microbial species.
In vitro polymicrobial models
• The development of in vitro polymicrobial models provides a cost-effective, tractable and robust system for
studying subtle interspecies interactions.
• In vitro models potentially allow long-term, ‘chronic infection’ to be recapitulated.
• Artificial sputum media is a defined synthetic medium closely mimicking the nutritional composition of
CF-derived sputum. artificial sputum media provides a physiologically relevant in vitro culture medium to permit
the growth of CF-associated species.
• Using sections of porcine lungs, an ex vivo culture system has been developed that introduces a spatial structure
similar to that of the CF-airway into in vitro models.
In silico polymicrobial models
• In silico models can be used to accurately recapitulate polymicrobial communities from published experimental
data inputs, and can yield information that may be difficult to obtain experimentally, but can help to guide
experimental design in in vitro and in vivo models.
• Such models are limited by the quality and quantity of data gathered from experimental studies and so poorly
represent hard-to-cultivate microbial species. However, as more (and better) input data is gathered, in silico
models will inevitably improve.
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